INT175034

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.09
First Reported 2003
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 3
Total Number 4
Disease Relevance 3.05
Pain Relevance 0

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell differentiation (Mecom) nucleus (Mecom) intracellular (Mecom)
DNA binding (Mecom)
Mecom (Mus musculus)
Pain Link Frequency Relevance Heat
antidepressant 1 39.60 Quite Low
cva 1 31.20 Quite Low
Arthritis 1 29.60 Quite Low
Pain 8 5.00 Very Low Very Low Very Low
depression 3 5.00 Very Low Very Low Very Low
addiction 2 5.00 Very Low Very Low Very Low
Pain management 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Myelodysplastic Syndromes 117 100.00 Very High Very High Very High
Myeloid Leukemia 54 100.00 Very High Very High Very High
Leukemia 20 100.00 Very High Very High Very High
Myelofibrosis 2 99.76 Very High Very High Very High
Chronic Myelomonocytic Leukemia 2 91.20 High High
Decubitus Ulcers 12 87.32 High High
Disease 14 70.08 Quite High
Emergencies 1 41.80 Quite Low
Incontinence 8 39.36 Quite Low
Mental Disorders 1 32.28 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The weights used in the derivation of MDS-HSI are reflective of a community-based population and, therefore, might understate or overstate the LTC residentsÂ’ own perceptions of their utility scores.
Positive_regulation (derivation) of MDS-HSI associated with myelodysplastic syndromes
1) Confidence 0.09 Published 2009 Journal Qual Life Res Section Body Doc Link PMC2804787 Disease Relevance 0.32 Pain Relevance 0
All relevant sources of information regarding resident status, including medical records, communication with residents and staff (including the CNA most familiar with the resident), and observation of residents, were to be utilized in determining the codes to be used for each of the 100 MDS items included in the reliability study.
Positive_regulation (used) of MDS associated with myelodysplastic syndromes
2) Confidence 0.09 Published 2003 Journal BMC Health Serv Res Section Body Doc Link PMC280691 Disease Relevance 0.43 Pain Relevance 0
As to WT1 peptide vaccination for patients with leukemia, WT1 peptide vaccination for AML 20, 26, overt leukemia from MDS, and MDS with myelofibrosis 27 have been previously reported.
Positive_regulation (vaccination) of MDS associated with leukemia, myeloid leukemia, myelodysplastic syndromes and myelofibrosis
3) Confidence 0.05 Published 2010 Journal International Journal of Medical Sciences Section Body Doc Link PMC2860640 Disease Relevance 1.15 Pain Relevance 0
As to WT1 peptide vaccination for patients with leukemia, WT1 peptide vaccination for AML 20, 26, overt leukemia from MDS, and MDS with myelofibrosis 27 have been previously reported.
Positive_regulation (vaccination) of MDS associated with leukemia, myeloid leukemia, myelodysplastic syndromes and myelofibrosis
4) Confidence 0.02 Published 2010 Journal International Journal of Medical Sciences Section Body Doc Link PMC2860640 Disease Relevance 1.15 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox